fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Olsalazine sodium

All products: general benefit

Dipentum · DIN 02063808 · 250 mg · capsule

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Dipentum · DIN 02063808 Manufacturer: Atnahs Pharma UK Limited; listing date 2009-05-20 Health Canada: Marketed since 2025-04-08 · brand DIPENTUM · ATC A07EC03 OLSALAZINE · form Capsule · route Oral · ingredients OLSALAZINE SODIUM 250 MG · company 2235721 alberta ltd. / sunshine environmental · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Dipentum: Formulary list price $0.53 per unit (the source does not state the unit; exact figure $0.5330). What the ministry pays, not the patient.

Ministry pays: $0.5330 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02063808)

Source record
DIN 02063808: Dipentum Raw flags: sec3=Y Item: 564000047; group id 687; item number 1708; lccId None; manufacturer id APU Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.5330; ministry $0.5330 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02063808 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17893
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (A07E, A07EC): coverage varies; not interchangeable

  • Aminosalicylic acid (Mezera): general benefit, not a benefit
  • Mesalazine (Octasa): general benefit
  • Budesonide (Uceris): general benefit
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

5-AMINOSALICYLIC ACID

· 17 products · General benefit (16), Listed, not a benefit (1) · strengths: 1g/Actuation, 500mg, 1.2g, 1g, 1g/100mL, 4g/100mL, 4g, 1000mg, 400mg · 14 Actuation-Foam Enema Canister Pk, Del-Release Tab, Delayed & ER Tab, DR Tab, Enema, Ent Tab, ER Tab, Rect Susp-Pk, Sup, Tab

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

DOMPERIDONE MALEATE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 10mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

METOCLOPRAMIDE HCL

· 8 products · Limited Use, codes 481, 657 (2), Listed, not a benefit (2), General benefit (4) · strengths: 5mg/mL, 5mg, 10mg · Inj Sol (Preservative Free), Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS DIPENTUM (olsalazine sodium capsule) is indicated for: • Long-term maintenance of patients with ulcerative colitis in remission. • Treatment of acute ulcerative colitis of mild to moderate severity, with or without the concomitant use of steroids. 1.1 Pediatrics Pediatrics (≤ 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. https://pdf.hres.ca/dpd_pm/00080174.PDF PM date: APR 08, 2025 Source product: DIPENTUM; DIN 02063808; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.